+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

E

Actively Recruiting

This research evaluates the safety and tolerability of gilteritinib in adults with locally advanced or metastatic ALK-positive non-small cell lung cancer NSCLC who have stopped responding to previous ALK inhibitor treatments, including alectinib or lorlatinib. The study addresses the unmet medical need caused by changes in the faulty ALK gene that make current treatments less effective over time. Gilteritinib, already approved for certain leukemia cases, may block these ALK gene changes in NSCLC. Participants will take gilteritinib tablets once daily in 28-day cycles. They will start on a lower dose and may increase to a higher dose if they tolerate it and meet safety criteria. While on the study, participants will have regular tumor scans and continue treatment until cancer progression, intolerance, choice to stop, start of other cancer therapies, or death. After stopping gilteritinib, clinic visits will occur about 7 and 30 days later for safety checks, followed by ongoing tumor scans if cancer has not worsened. Throughout the study, participants will be monitored for adverse events, lab abnormalities, vital signs, ECG changes, and physical exam findings. Safety and response will be assessed for up to about 53 months, with pharmacokinetics measured up to 6 months. After treatment ends, participants will receive health check phone calls every 12 weeks and may remain in the study for up to 4 years depending on their response to gilteritinib.

Age: 18Years +All GendersPhase 1
17 locations
S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to explore how heat exposure treatments affect adults aged 18 to 65 who are currently experiencing depressive symptoms. The study will compare the effects of a single Whole Body Hyperthermia heat therapy session alone versus the same heat session followed immediately by a cold water plunge. The goal is to understand whether adding cold exposure after heat therapy can improve emotional well-being in people with depression. Participants will be randomly assigned to one of two groups. One group will receive a single heat treatment using the Clearlight Sauna Dome for up to 140 minutes. The other group will receive the same heat session followed immediately by a cold water plunge lasting up to 10 minutes in 55-degree Fahrenheit water. A second group of adults without depression will undergo the same treatments for comparison. During the study, participants will complete assessments of their depressive symptoms at baseline, and then again at 1 week and 2 weeks after treatment. Researchers will use tools such as the Montgomery-sberg Depression Rating Scale to measure changes in mood. Participants will also complete other questionnaires assessing mental well-being, anxiety, disability, and quality of life. The study will monitor participants throughout the study visits and follow-ups to evaluate the treatment effects on depression.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.

Age: 18Years +All GendersPhase 2
182 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.

Age: 18Years +MALEPhase 3
395 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
S

Actively Recruiting

Researchers are evaluating the effects of a single dose of psilocybin combined with psychological support on adults aged 18 to 70 who have experienced a major depressive episode lasting at least 60 days. The study also compares different post-dosing interventions, including a device called transcutaneous auricular Vagus Nerve Stimulation taVNS, to see how they affect psychological and behavioral outcomes. The trial aims to understand real-world social behavior and identify early responses linked to long-term results. All participants will receive one 25 mg dose of synthesized psilocybin under careful preparation and support, including preparatory sessions, facilitators during dosing, and post-dosing integration sessions. After dosing, participants are randomly assigned to one of three groups twice daily taVNS sessions for 7 days, twice daily sham taVNS sessions for 7 days, or no taVNS. The taVNS and sham sessions include music and guided reflections related to the psilocybin experience. Participants will undergo multiple assessments before and after dosing to measure depression, anxiety, well-being, quality of life, social roles, suicidal thoughts, and any adverse events. Data collection includes questionnaires and devices that record social behavior and experiences over several weeks. The main outcomes focus on depression scores, social participation, and quality of life, with follow-up assessments continuing up to 8 weeks post-dose to monitor effects and safety.

Age: 18Years - 70YearsAll GendersPhase 2
1 location

1-10 of 18

1